Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

17 Aug 2011 15:29

RNS Number : 5538M
GW Pharmaceuticals PLC
17 August 2011
 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED COMPANY SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

77,900 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

77,900 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

507,146 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

282,958 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

115,870 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

367,088 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

200,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

618,659 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

906,592 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

212,067 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

500,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

350,400 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

349,600 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

400,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS LONG TERM INCENTIVE PLAN 2008

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

600,000 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

600,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

 

 

For further information, please contact:

 

Adam George, Company Secretary, GW Pharmaceuticals plc

 

Telephone: +44 (0)1980 557000

 

James Steel/Vijay Barathan, Nominated Adviser, Peel Hunt LLP

 

Telephone: +44 (0)20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRZDLFFFVFLBBD
Date   Source Headline
13th Dec 20104:15 pmRNSDirector/PDMR Shareholding
9th Dec 20102:39 pmRNSPublication of Annual Report
8th Dec 20103:52 pmRNSDirector/PDMR Shareholding
3rd Dec 20107:00 amRNSChange of Adviser
29th Nov 20104:31 pmRNSDirector/PDMR Shareholding
23rd Nov 20107:01 amRNSSativex Enters Phase III Cancer Pain Programme
23rd Nov 20107:00 amRNSFinal Results
19th Nov 201010:10 amRNSUpdate on Nomad and Broker Position
3rd Nov 20107:00 amRNSSativex Approved in New Zealand for MS Spasticity
21st Oct 201011:30 amRNSNotice of Results
21st Oct 201011:30 amRNSNotice of Results
14th Oct 20109:30 amRNSResearch Update
13th Oct 201012:12 pmRNSHolding(s) in Company
30th Sep 20107:03 amRNSGW Starts Phase IIa Study Programme
22nd Sep 20107:00 amRNSSativex Study Results Published in Peer Journal
16th Sep 20109:29 amRNSHolding(s) in Company
16th Sep 20109:28 amRNSHolding(s) in Company
14th Sep 20105:16 pmRNSDirector/PDMR Shareholding
9th Sep 201011:51 amRNSDirector/PDMR Shareholding
31st Aug 20107:00 amRNSHealth Canada Grants Full Approval of Sativex
3rd Aug 20107:00 amRNSDirector/PDMR Shareholding
28th Jul 20107:00 amRNSSativex receives regulatory authorisation in Spain
27th Jul 20107:00 amRNSDirectorate Change
23rd Jul 20105:10 pmRNSDirector/PDMR Shareholding
19th Jul 20103:33 pmRNSDirector/PDMR Shareholding
5th Jul 20105:35 pmRNSDirector/PDMR Shareholding
2nd Jul 201010:03 amRNSResponse to Media Comment
30th Jun 20107:00 amRNSGlobal Cannabinoid Research Collaboration Extended
22nd Jun 201011:23 amRNSGW Pharma to present at Piper Jaffray Conference
21st Jun 20107:00 amRNSUK Launch of First Prescription Cannabis-Medicine
18th Jun 20102:33 pmRNSProduct Update
11th Jun 20103:36 pmRNSDirector/PDMR Shareholding
20th May 20107:00 amRNSInterim Results
11th May 20104:21 pmRNSNotice of Results
28th Apr 20104:40 pmRNSSecond Price Monitoring Extn
28th Apr 20104:35 pmRNSPrice Monitoring Extension
31st Mar 20105:28 pmRNSTotal Voting Rights
25th Mar 20104:07 pmRNSDirector/PDMR Shareholding
24th Mar 20105:21 pmRNSHolding(s) in Company
24th Mar 20102:55 pmRNSResult of AGM
23rd Mar 20103:44 pmRNSHolding(s) in Company
23rd Mar 20103:38 pmRNSHolding(s) in Company
23rd Mar 20107:00 amRNSPositive Data in Sativex Phase IIb Trial
18th Mar 20107:00 amRNSSativex Regulatory Update
18th Jan 20105:27 pmRNSBlock Listing Application
15th Jan 201011:09 amRNSTotal Voting Rights
5th Jan 20104:35 pmRNSPrice Monitoring Extension
11th Dec 20098:57 amRNSDoc re. Annual Report
1st Dec 20097:00 amRNSChange of Adviser
26th Nov 20095:46 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.